PMUC1CALLO-1 is a gene-modified cell therapy commercialized by Poseida Therapeutics, with a leading Phase I program in Triple-Negative Breast Cancer (TNBC). According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of PMUC1CALLO-1’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The revenue for PMUC1CALLO-1 is expected to reach an annual total of $66 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
PMUC1CALLO-1 Overview
P-MUC1CALLO-1 is under development for the treatment of solid tumors derived from epithelial cells tumors including triple-negative breast cancer, renal cancer, ovarian cancer, non-small cell lung cancer, esophageal cancer, gastric cancer, pancreatic cancer and colorectal cancers. The drug candidate is administered through intravenous route. It comprises of allogeneic stem memory T cells (Tscm), genetically engineered to express chimeric antigen receptor (CAR). It acts by targeting the cells expressing mucin1. The therapeutic candidate is being developed based on Piggybac DNA modification system and CAS Clover gene-editing technology.
Poseida Therapeutics Overview
Poseida Therapeutics is a clinical-stage biopharmaceutical company that focuses on developing cell and gene therapies. Its activities leverage proprietary non-viral gene engineering technologies to create innovative cell and gene therapies. Poseida Therapeutics’ product pipeline includes P-PSMA-ALL01 and P-MUC1C-ALLO1 for the treatment of solid tumors. Poseida Therapeutics other pipeline products include P-BCMA-ALLO1, P-BCMACD19-ALLO1, P-CD19CD20-ALLO1, and P-CD70-ALLO1 for the treatment of hematologic malignancies and autoimmune diseases. It also develops several liver-directed gene therapies comprising KLKB1-101 and P-FVIII-101. The company works in partnership with Roche and Astellas. Poseida Therapeutics is headquartered in San Diego, California, the US.
The company reported revenues of (US Dollars) US$64.7 million for the fiscal year ended December 2023 (FY2023), a decrease of 50.4% over FY2022. The operating loss of the company was US$129.5 million in FY2023, compared to an operating loss of US$60 million in FY2022. The net loss of the company was US$123.4 million in FY2023, compared to a net loss of US$64 million in FY2022.
The company reported revenues of US$26 million for the second quarter ended June 2024, a decrease of 7.7% over the previous quarter.
For a complete picture of PMUC1CALLO-1’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
